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RESUMEN 
La Farmacia Comunitaria forma parte del sistema de salud. Este sistema actualmente se encuentra 
sometido a presiones económicas y debe afrontar cambios en la demanda tanto de los consumidores 
como de los gobiernos. La respuesta de la profesión farmacéutica está dirigida a orientar su práctica 
hacia el paciente y a implantar servicios cognitivos farmacéuticos (CPS). En distintos países estos 
servicios tiene objetivos similares aunque presentan diferencias en el énfasis de los servicios, en sus 
definiciones, denominaciones y en la utilización de diferentes herramientas. Sin embargo, todos ellos 
pueden clasificarse utilizando un amplio modelo jerárquico que se basa en la toma de decisiones 
clínicas y en la amplitud del cambio requerido. (Box 1). Los retos que debe afrontar la profesión están 
relacionados con el desarrollo de un nuevo modelo de farmacia orientado al paciente que afecta  a las 
políticas de salud, a la formación e investigación, a la evolución de los mercados, a los abordajes del 
cambio tanto  a nivel individual como organizacional, y a la implantación de CPS. Estos temas y la 
investigación  en  práctica  farmacéutica  que  se  ha  venido  realizando  con  anterioridad  han  sido 
sintetizados  para   proporcionar  una  plataforma  para  el cambio  que  pueda  guiar  un  planteamiento 
holístico  e  integrado  de  implantación  de  CPS.  Conceptualmente  la  implantación  de  CPS  puede 
enmarcarse  en  seis  niveles:  clínico,  provisión  de  servicios,  farmacia  comunitaria,  organización 
profesional, gobierno y agentes implicados (Figura 1). La experiencia reciente relacionada con la 
implantación de servicios ha mostrado la aplicación de programas de implantación que han incluido 
uno o dos de estos niveles en lugar de haber utilizado un abordaje holístico. Por ello se ha desarrollado 
un modelo concéntrico para ilustrar la implantación de CPS dentro del planteamiento integrado y 
holístico necesario para apoyar el cambio En España se ha desarrollado un programa (conSIGUE) que 
pretende integrar los seis niveles con el objetivo de apoyar la implantación y evaluación de un CPS, el 
servicio de seguimiento farmacoterapéutico. 
PALABRAS  CLAVE:  Implantación.  Servicios  cognitivos  farmacéuticos.  Farmacia 
comunitaria. Gestión del cambio 
ABSTRACT 
Community pharmacy is part of the health care system which is currently under economic pressure 
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profession is becoming more patient orientated and implementing cognitive pharmaceutical services 
(CPS). CPS in various countries has similar objectives with different emphasis, definitions, labels and 
using different tools. However, they can be classified using a broad hierarchical model based on 
clinical decision making and the extent of change required (Box 1).  The challenges faced by the 
profession are related the development of a new patient orientated model of pharmacy which affects 
health  care  policy,  education  and  research,  the  evolution  of  the  market,  the  individual  and 
organisational  approaches  to  change  and  the  implementation  of  CPS.  These  issues  and  previous 
research conducted in pharmacy practice have been synthesised to provide a platform for change that 
can  guide  a  holistic  and  integrated  approach  to  CPS  implementation.  Implementation  can  be 
conceptually  framed  in  six  levels:  clinical,  service  provision,  community  pharmacy,  professional 
organisation, government and stakeholder (Figure 1). Past experience with service implementation has 
seen the application of programs that include one or two of these levels in practice rather than a 
holistic approach. A concentric model was developed to illustrate the implementation of CPS and the 
holistic and integrated approach required to support change. A program (conSIGUE) being conducted 
in Spain has attempted to integrate all six levels to support the implementation and evaluation of a 
medication management service (Seguimiento Farmacoterapéutico)  
 
KEYWORDS:  Implementation.  Cognitive  pharmaceutical  services.  Community  pharmacy. 
Change management. 
   
INTRODUCTION 
Community pharmacy is part of the health care system which is currently under economic 
pressure and facing changes in demands from consumers and government.
1,2  The pharmacy 
profession is changing to become more patient orientated and to introduce health services in 
an effort to optimise the use of medications and reduce the morbidity and mortality related to 
therapeutic regimens.  
The current challenges facing health care are made more complex by issues such as the 
ageing  population,  new  technologies,  transmission  of  communicable  diseases,  consumer 
expectations, the increasing burden of chronic conditions and increasing costs.
3 Additionally, 
health and drug related problems are often associated with the suboptimal use of medications; 
both prescribed and self-administered.
4 As governments are facing increasing demand from 
many competing sources, expenditure dedicated to health care is under scrutiny and there are 
limited  funds  allocated  to  address  changing  needs.  Hence,  new  methods  of  health  care 
provision  are  required.
3  Suggested  solutions  include  the  redesign  of  entire  health  care 
systems, the creation of multi-disciplinary teams to provide health services and the use of 
technology  to  create  efficiencies  in  the  system.
5,6  Additionally,  community  pharmacy  has 
been recognised as an underutilised resource. To ease the burden on existing systems in some 
countries,  the  professional  pharmacy  organisations,  government  and  consumers  have 
encouraged the profession to introduce health services, or cognitive pharmaceutical services 
(CPS), into daily practice. 
7   
CPS in various countries has similar objectives with different emphasis, definitions, labels 
and using different tools. However, they can be classified using a broad hierarchical model 
based on clinical decision making and the extent of change required (Box 1). For example, the 
provision of medicines information could be said to require less clinical decision making as 
compared to prescribing. Similarly, the model attempts to order the degree of change required BENRIMOJ SL et al.  Un enfoque holístico e integrado de la implantación de los servicios…              71 
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from  the  pharmacist’s  traditional  role  and  practice  environment  to  provide  services.  The 
model has limitations in its capacity to categorise product based services. For example, dose 
administration aids (DAA) may be considered to be enablers for adherence and thus may be 
part of compliance service.  
 
Box 1: Hierarchical Model of Cognitive pharmaceutical services 
 
1.  Medicines Information
8 
2.  Compliance, Adherence and/or Concordance
9  
3.  Disease Screening
10 
4.  Disease Prevention
11 
5.  Clinical Intervention or identification and resolving Drug Related Problems
12 
6.   Medication Use Reviews
13 
7.  Medication management/medication therapy management
14-16 
a.  Home Medication Reviews 
b.  Residential Care Home Medication Reviews 
c.  Medication reviews with continuance follow up 
8.  Disease State Management for Chronic Conditions
17 
9.  Participation in therapeutic decisions with Medical Practitioners
18,19 
a.  In Clinical setting 
b.  In the pharmacy 
10.  Prescribing
20 
a.  Supplementary  
b.  Dependent 
 
CHALLENGES OF CHANGE IN PHARMACY 
Within the profession, change is politically supported. It is supported by international and 
national  professional  pharmacy  associations  through  the  development  of  the  community 
pharmacist’s role. Patients recognise the benefits of CPS, as illustrated by their insistence in 
receiving  patient  information.  CPS  provision  aids  government  achieves  a  quality  use  of 
medicines  and  their  cost  reduction  agenda.  Community  pharmacists  have  been  able  to 
decrease  health  care  expenditure  and  decrease  morbidity  rates by preventing  drug  related 
problems through the provision of CPS.
13 The benefit of a change in pharmacy has been 
acknowledged through the adoption of initiatives by governments and more recently by the 
health insurance companies and pharmaceutical companies.
21,22 These initiatives have been 
largely based on providing remuneration for CPS to stimulate service provision. There is a 
clear growing trend to remunerate CPS in countries such as United Kingdom, United States of 
America,  Australia,  Belgium,  Switzerland  and  Portugal,  demonstrating  that  government 
policy has provided support a patient orientated model of pharmacy.
7,23,21,24,25  BENRIMOJ SL et al.  Un enfoque holístico e integrado de la implantación de los servicios…              72 
Ars Pharm, 2010, 51-2; 69-87. 
 
The  integration  of  CPS  into  the  daily  practice  of  a  community  pharmacy  produces  a 
dilemma resulting from the nature of its operating environment. In practice, the community 
pharmacy operating environment is not exclusively health care or patient focused; the retail 
context of community pharmacy presents a unique challenge.
26-28 It merges the commercial 
necessity to run  a financially viable and accountable business with the need to  configure 
operations  to  meet  appropriate  standards  of  professional  conduct  and  competence.
29  
Economic,  regulatory  and  organizational  frameworks  influence  the  role  of  community 
pharmacists through setting standards and commercial limitations of pharmacies as a health 
care  retailer.
28  Change  for  community  pharmacy  implicates  interaction  with  external 
stakeholders (e.g. government bodies, consumers, universities, pharmaceutical industry and 
influencing parties). 
HEALTH CARE POLICY IMPLICATIONS 
In relation to community pharmacy, national governments have used two key strategies to 
manage health policy and expenditure, regardless of country or prevailing political party.
30 
These  policies  control  health  care  costs  through  the  reduction  in  medication  mark-ups, 
margins  and  reference  pricing  as  well  as  the  flow  on  effects  from  the  increased  use  of 
generics.
31 Secondly, following WHO policy initiatives, national governments have begun 
integrating quality use (QUM) and/or rational use of medicines (RUM) principles into their 
health agendas.
3 The QUM and RUM policies directly and indirectly support the new patient 
orientated  model.
3,7,32  Some  governments  recognise  CPS  provision  as  a  cost  effective 
medication  management  tool,  which  increases  quality  of  life  and  reduces  morbidity  and 
mortality  in  targeted  high  cost  and  other  patient  populations  such  as  poly-pharmacy 
residential  care  and  geriatric  ambulatory  patients.
14  Government  policy  also  encourages 
chronic  disease  management  particularly  through  the  increased  use  of  multi  disciplinary 
teams.
5,33  
All health care services can be classified through a spectrum: prevention, early detection, 
diagnosis and assessment, treatment, rehabilitation and palliation.
28 In moving through this 
spectrum to identify new opportunities for community pharmacy, a balance must be struck 
between expanding the role of pharmacists and crossing traditional role boundaries, although 
these  boundaries  are  increasingly  being  questioned.  Professional  collaboration  within  the 
health care system is ideal but the increased sense of competition and working outside the 
pre-existing definitions of professional roles have caused tension between pharmacists and 
other  groups,  such  as  physicians.  In  an  attempt  to  overcome  these  issues,  professional 
associations  are  pursuing  collaborative  agreements  at  a  political  level  and  individual 
pharmacists are working with their local health care partners.
19,34  
EDUCATION AND RESEARCH 
In the area of education, the introduction of CPS has stimulated universities to various 
levels  of  action.  Initially,  curriculums  were  revised  for  undergraduate  and  postgraduate 
courses to educate students in these areas and a concurrent development of pharmacy practice BENRIMOJ SL et al.  Un enfoque holístico e integrado de la implantación de los servicios…              73 
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research  began.
35,36  The  more  sophisticated  changes  such  as  joint  teaching  with  other 
professions to provide the foundation for future collaborative working environments have not 
yet been developed sufficiently in most countries.
37 It could be suggested that the growth of 
pharmacy  practice  research  has  given  academic  opinion  leaders  the  ability  to  influence 
changes  in  professional  practice  and  emphasised  evidence  based  change.  Research  and 
teaching  has  been  stimulated  through  the  appointment  of  professors  and  academic  staff 
dedicated to pharmacy practice.
38,39 In many countries, this was followed by the creation of 
the discipline of pharmacy practice or/and departments with similar objectives and varied 
titles.
38  Pharmacy  practice  has  tended  to  be  the  overall  arching  discipline  incorporating 
clinical,  administrative  and  social  pharmacy,  behavioral  studies,  pharmaco-epidemiology, 
health  economics,  marketing  and  management.    The  rate  and  pace  of  adoption  of  this 
educational and research change has varied between and within countries.  It could be said 
that the American and Anglo Saxon university models have changed more rapidly while some 
European universities have been slower. In Europe, the Bologna declaration has stimulated 
debate and resulted in some changes.
40,41 However within countries there are examples where 
the  change  has  been  rapidly  adopted.  The  negative  impact  of  the  slower  adoption  of 
educational change is evidenced when pharmacists enter the workforce unprepared to provide 
CPS. 
DEVELOPMENT OF THE MARKET 
The  pace  of  change  created  by  government  policy,  professional  organisations  and 
universities has challenged community pharmacies and pharmacists to evolve and maintain 
their relevance in the market.
26,42 Community pharmacies changing to a patient orientated 
model requires management and structural changes to the business. 
26,27,42,43 At the same time 
community pharmacy viability has been put at risk because of the reduced profit margin in 
their traditional core business – dispensing medication and the perception that the return on 
investment of services is low.
26,42,44  Some pharmacies have moved toward creating a position 
in the market based on providing CPS while an alternative market segment  is focused on 
convenience and deep discounting in product provision.
28,44,45 Currently, the pharmacy market 
is  differentiating  into  these  two  broad  segments.  The  principles  of  market  differentiation 
suggest that all organisations in an industry cannot provide identical services, eliminating the 
competition in the market.
46 In the “so called” liberalised markets of the United Kingdom, 
Canada, Iceland, Norway and United States, corporatized pharmacies are more common with 
few  independently  owned  community  pharmacies.
7  Larger,  supermarket  style  pharmacies 
with a product/retailing orientation are prevalent. Other countries with a regulated market, 
such  as  Australia,  Spain,  France  and  Italy,  are  dominated  by  smaller,  independent 
pharmacies.
40 In some of these markets, the opportunity for the emerging, service orientated 
model of pharmacy is being closely pursued to compete with the product/retail model.
44  
ADDRESSING CHANGE 
Change in community pharmacy has traditionally been addressed in two ways. Firstly, an 
individual practitioner’s point of view has been taken using change theories and strategies BENRIMOJ SL et al.  Un enfoque holístico e integrado de la implantación de los servicios…              74 
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largely focused on their behavioural change.
47,48Secondly, recent research has focused on the 
organisational  level  analysis  in  addition  to  the  individual  perspective.
49,50  Some  of  this 
research has used management theories to analyse service integration in practice and promote 
CPS  implementation  and  sustainability.
42,45      Furthermore  an  innovative  Australian  study 
focused on building capacity in community pharmacy used the framework of organisational 
flexibility  (OF)  to  research  CPS  implementation.
27,44  OF  is  a  key  business  objective  to 
improve  viability  in  a  changing  environment.
51    The  concept  originally  referred  to  the 
capacity of organisations to proactively and successfully adapt in a dynamic environment.
52 
Volberda defined OF as “the degree to which an organisation has a variety of managerial 
capabilities and the speed at which they can be activated, to increase the control capacity of 
management and improve the controllability of the organisation”.
53 Feletto et al applied OF to 
community  pharmacies  using  a  pre-existing  scale  to  measure  the  type  of  flexibility  in 
organisations.
54  The  study  illustrated  the  benefit  of  applying  management  frameworks  to 
community  pharmacy,  identified  capacity  building  and  strategic  decision  making  by 
pharmacy owners as critical factors to enable and sustain implementation of CPS.
54  
IMPLEMENTATION 
Service implementation is complex and represents an area in which community pharmacy 
has had limited past experience. Pharmacists have expressed the need for more assistance in 
guiding the implementation of services.
27,28 Evidence has shown that CPS provision can result 
in  a  viable  pharmacy  practice,  nonetheless  the  perception  by  pharmacy  owners  that  this 
viability cannot be sustained in the long term has hindered service implementation. 
27,42,44 
There is an existing reliance on dispensing medications as the key source of income supports 
the product orientated model. The challenges in optimising viability through CPS provision 
include payment for services to reduce community pharmacy reliance to product supply and 
validating any cost to patients and/or third party payers.
42 There has been criticism of the lack 
of implementation even when payment has been available for service provision. Much of this 
lack  of  implemenatation  has  been  attributed  to  practitioners.  However,  an  alternative 
hypothesis may be that there has not been a profession-wide, holistic integrated approach 
specific to pharmacists who wish to  adopt CPS.
42 The holistic integrated approach would 
incorporate  all  significant  factors  and  aid  in  capacity  building  of  pharmacy  owners  and 
pharmacy practitioners.
27,55  
Therefore the objective of this article is to provide a platform for change that can guide this 
holistic and integrated approach to service implementation in the profession. 
HOLISTIC AND INTEGRATED MODEL 
The  issues  outlined  above,  combined  with  evidence  from  pharmacy  practice  research 
identified six key levels of change encapsulated in a holistic approach to implementation of 
services  in  community  pharmacy  (Figure  1).  This  approach  is  based  on  an  analysis  of 
historical developments, practice experience and evidence based research.  BENRIMOJ SL et al.  Un enfoque holístico e integrado de la implantación de los servicios…              75 
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Figure 1: Holistic approach to service implementation 
 
 
CLINICAL LEVEL 
The initial response by professional organisations and universities to CPS was to develop 
initiatives  to  improve  the  clinical  competencies  of  community  pharmacist.
35,36    Clinical 
practice  is  the  foundation  of  pharmacy  practice  and  is  supported  through  continued 
development of pharmacists’ clinical skills and competencies.
35 The focus of clinical practice 
is to improve patients’ health outcomes, optimise pharmacist-patient relationship and increase 
collaboration  with  other  health  care professionals.
56  The  first  reaction  by  universities  and 
professional  organisations  to  change  was  to  offer  clinical  modules  modeled  on  medical 
courses  and  mainly  concentrating  on  disease  states  and  medications.  Later  development 
included the addition of case studies in these programs to have a greater emphasis on practical 
application.
36  During  this  phase,  research  began  to  focus  on  interventions  leading  to 
behavioural changes that impact on patient consultations and on change to the attitude and 
perceptions  of  individual  pharmacists.
47    Although  it  made  logical  sense  to  increase  the 
clinical competency of individual pharmacists and increase patient contact it became evident 
that  CPS  implementation  would  not  be  sustainable  without  additional  enablers.  In  some 
countries, proactive practitioners commenced providing services but these were inconsistent. 
Much  of  the  research  at  this  time  began  to  identify  barriers  with  payment  for  services 
identified as a major issue.
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SERVICE PROVISION LEVEL 
In 1990 Hepler and Strand, with the publishing of the conceptual paper on Pharmaceutical 
Care had an impact on the profession worldwide.  However, the concept had to be translated 
to service provision at the community level.
2 Following, research based on evaluation of the 
impact of CPS produced with a major objective of defining specific services, classification 
systems, and methodologies, evaluating the clinical, economic and humanistic impact and 
generating data to negotiate service payments.
13,15,17 Services and educational programs were 
designed for medication management and reviews, chronic disease states, such as asthma and 
diabetes.  Studies  provided  clear  and  useful  guidelines  for  the  application  of  the  clinical 
knowledge to practice through service provision frameworks. The implementation of services 
was slower than anticipated and sparked further research to uncover the barriers to service 
implementation.
60-62 The major barriers cited, reinforcing previous findings, were the time 
involved  and  lack  of  remuneration  for  service  delivery.
60-62  Research  into  facilitators  of 
practice change began to undertaken. At the professional organisation level it was thought that 
if payment was provided, and coupled with clinical competence, implementation would be 
inevitable. In hindsight this level overlooked the context of the environment in which the 
service was being undertaken, that a pharmacy is a business needing to maintain its viability.  
COMMUNITY PHARMACY LEVEL 
The limited implementation in practice then stimulated work which considered community 
pharmacies as individual organisations with competing objectives of providing health care 
and maintaining their viability.
26,28,42 Research was conducted to identify the facilitators of 
implementation  to  understand  how  services  could  be  more  effectively  adopted.
63  This 
research identified new barriers and facilitators which helped to better understand and target 
activities  to  promote  the  uptake  of  services.
60,61,63  Factors  were  identified  that  included 
specific  management  skills  such  as  delegating  and  leading,  managing  staff,  internal 
communication,  pharmacy  layout,  enhancing  external  stakeholder  relationship,  managing 
consumer  expectation  and  marketing.
60,61,63  An  important  concept  was  the  growing 
acceptance of professional organisations that payment for service delivery was essential but 
not the sole critical factor for implementation.
42,61,64 Sustainable delivery of services would 
require fundamental changes to daily professional and business practices and practice change 
needed to integrate the business and health care elements of community pharmacy.
42,65 
PROFESSIONAL ORGANISATION LEVEL 
Implementing business and professional aspects requires change in community pharmacies 
and support from professional pharmacy organisations.
27,61 Professional organisations can be 
divided into two types, those that represent the professional role of pharmacists and those that 
represent their business requirements.  In some countries there are organisations that merge 
these two interests, but these are generally dominated by pharmacy owners.  In some cases 
this could be the cause of the limited integration of professional and business issues. These 
organisations often compete to provide support services required by pharmacists in practice, BENRIMOJ SL et al.  Un enfoque holístico e integrado de la implantación de los servicios…              77 
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which  consequently  results  in  a  delay  in  the  provision  of  the  necessary  support.
27,28 
Professional organisations need significant changes to organisational policies, resources and 
internal  infrastructure.  The  existing  product-based  focus  and  subsequent  product  based 
remuneration  currently  supported by  the professional  organisations  needs  to be  shifted  to 
further support CPS provision and a patient orientated model.
32,44,55 Alongside the change 
required at the community pharmacy level, it is essential that professional organisations adapt 
their support systems to address the needs of practicing pharmacists.  This implies a change in 
the traditional role of professional organisations from their normal activities to include setting 
professional standards, lobbying with stakeholders, negotiating payment for services and the 
introduction of adequate support systems for pharmacists and pharmacy. This would require 
significant  internal  reorganisation  and  restructuring  which  has  not  occurred  in  many 
organisations to date.
7,32,66  
Practice  based  research  has  begun  to  incorporate  the  role  of  the  profession  and  their 
respective  associations  in  providing  support  through  infrastructure,  policy  or  resources  in 
planning for sustainable CPS delivery. Clear strategic initiatives from the profession need to 
be  mapped  through  more  extensive  empirical  research.  Few  studies  have  focused  on 
providing  concrete  directions  for  professional  organisations.  On  the  positive  side,  where 
remuneration for services has existed for more than ten years there is evidence of internal 
restructuring of professional organisations.
67 Sustainable changes to a patient focused model 
integrating  CPS  requires  the  support  from  professional  organisations.
60,61,65  Without  this 
support  it  could  be  assumed  that  service  implementation  will  continue  to  lag.  The 
incorporation  of  the  concept  of  a  patient  orientated  model  into  the  strategic  direction  of 
professional  organisations  is  a  necessary  pillar  for  ensuring  the  success  of  CPS 
implementation. 
GOVERNMENT LEVEL 
Professional organisations and individual pharmacists appear to perceive an unwillingness 
of national governments to provide remuneration for CPS. The main role of government is 
seen by pharmacists as being solely associated with cost reduction initiatives and reduction of 
product  margins.  However,  evidence  suggests  otherwise.  A  number  of  governments  have 
instigated reforms to the health care systems which directly benefit pharmacy and support 
CPS  provision.
7,32,66  However,  Government’s  objective  is  to  ensure  appropriate  use  of 
taxpayer funds.
30,22 They require value to be proven before allocating funds to CPS provision 
payments.    In  many  counties  the  prerequisite  for  approving  CPS  remuneration  has  been 
rigorous scientific research findings illustrating the cost effectiveness of pharmacists’ clinical 
interventions.
22 These finding alone are not always sufficient, CPS must be placed in the 
existing  government  agenda.
68,69  In  some  cases  third  parties,  such  as  consumers,  have 
pressured  governments  to  remunerate  CPS  relating  to  the  provision  of  medication 
information. However, research on the impact of government policy on CPS is sparse.  
Past experience has suggested that payment for services alone is not sufficient to support 
sustainable CPS provision.
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beyond  facilitating  a  service payment.  This  includes  resource  and  intellectual  support  for 
community pharmacy. Some governments have sponsored initiatives that provide quality and 
accreditation frameworks for pharmacy with associated incentives.
21,23,41,70 There have been 
financial incentives provided to encourage infrastructure changes and the implementation of 
quality assurance systems.
66  
The recognition of community pharmacy as an integral part of the health care system and 
pharmacists  as  members  of  the  primary  health  care  teams  is  of  great  importance  to  the 
implementation process. There is now the need to cement the role of community pharmacy 
and pharmacists in multi disciplinary disease management teams through government policy. 
Governments do have a role not only in providing financial support for CPS but including 
community  pharmacy  in  health  policy.  When  governments  do  not  act  through  their  own 
initiatives then there should be a desire by pharmacy organisations to lobby. 
STAKEHOLDER LEVEL 
The final and overarching level is the stakeholder level. This level includes representatives 
external to the profession, such as patients, their organisations, and bodies of other health care 
professional groups such as physicians and nurses.
71-73 The literature only provides a limited 
analysis on the impact of these bodies on the implementation process and focuses primarily 
on two areas: (1) the use of pharmacies by consumers and/or their level of satisfaction with a 
given  service  and  (2)  collaborative  efforts between pharmacists  and  the  other  health  care 
professionals as part of a collective primary health care team, specifically physicians.
74,34,75  
The effect of CPS provision to external stakeholders can be illustrated using medication 
management  reviews  (MMR)  with  their  effect  on  physicians  and  patients.
19,74,34  A  key 
outcome  of  MMR  is  an  adjustment  in  the  patient’s  medication  therapy.  Without  this 
adjustment the review can be said to have limited application. The degree of collaboration 
between the physician and the pharmacist directly influences the success or failure of the 
MMR.  This  collaboration  can  be  influenced  by  the  interaction  between  physicians  and 
pharmacists at four levels: a national (professional organisation) level, a regional (state or 
provincial) level, a local health care team level (with a group of health care professionals) and 
an individual level in regards to a specific patient. Issues at any of these levels can affect the 
outcome of MMRs. 
In many countries there is open criticism by physicians regarding the provision of CPS. 
Generally, physicians consider pharmacists as lacking the competency to provide CPS. They 
also believe that CPS encroach on the physician’s professional role and are reluctant to share 
confidential  clinical  information  about  their  patients.  Community  pharmacies  are  seen  as 
focused on retailing rather than health care, thus motivated by improving their bottom line 
rather  than  the  patient’s  health.  If  left  unaddressed,  these  issues  can  impede  any  CPS 
implementation  program.  A  collaborative  relationship  with  local  physicians  has  been 
identified as a key facilitator MMR services.
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In contrast to the opinions held by physicians, patients who have been provided CPS have 
high rates of satisfaction but paradoxically consumer representative organisations are critical 
of the consistency of pharmacy performance.
8,77-79  Generally, pharmacy users are unaware of 
CPS and their benefits, thus there is little demand being generated.  As part of the retail 
environment,  community  pharmacists  are  highly  sensitive  to  consumer  demand  and 
expectations and suffer financially if they do not respond to user needs. They are accustomed 
to focus on improving waiting time and pricing to meet user demands but in regards to CPS 
provision  they  are  less  proactive.
80  Future  CPS  implementation  programs  should  include 
consumer awareness and internal marketing to promote the service. Overall, the importance of 
external  stakeholders  should  not  be  underestimated  as  they  provide  a  valuable  external 
stimulus. 
USING  THE  HOLISTIC  AND  INTEGRATED  APPROACH  IN  PRACTICE:  
CONSIGUE PROGRAM 
Past experience with service implementation has seen the application of programs that 
include one or two of levels described above rather than a holistic approach. A program 
(conSIGUE) being conducted in Spain has attempted to integrate all six levels to support the 
implementation  and  evaluation  of  a  medication  management  service  (Seguimiento 
Farmacoterapéutico). The overall aim of conSIGUE is to evaluate the clinical, economic and 
humanistic impact of the provision SFT in the  community pharmacy in the elderly poly-
pharmacy population. 
The  program  began  with  a  series  of  consultations  with  professional  organisations  and 
stakeholders  to  ensure  that  the  program  objectives  were  aligned  to  the  key  government 
objectives  in  Spain.  As  in  many  other  countries,  the  Spanish  elderly  poly-pharmacy 
population is a group placing high demand on the health care system because of their complex 
medication regimens and co morbidities.
81 The Spanish government considers this group as a 
priority  in  their  strategic  health  plans  for  the  future.
82  The  government  and,  the  major 
pharmacy professional association, such  as the  Consejo General de Colegios Oficiales de 
Farmacéuticos (CGCOF), have supported the delivery of medication related services through 
community  pharmacies.
83  To  plan  the  changing  role  of  pharmacy,  a  group  of  leading 
politicians,  professional  pharmacy  associations  and  non-university  and  university  research 
groups came together and in January 2008 produced a consensus outlining their commitment 
to  providing  three  key  CPS  through  community  pharmacies.  One  of  these  services  is 
Seguimiento Farmacoterapéutico (SFT), a medication management service.
84  
A  holistic  program  has  been  designed  to  gain  support  from  stakeholders,  professional 
organisations and to set up the service effectively in the pharmacies. Led by the University of 
Granada,  conSIGUE  has  obtained  support  from  the  Government,  CGCOF,  medical 
organisations  and  other  Spanish  universities  for  the  implementation  of  SFT  in  Spanish 
community pharmacies. The program is being  conducted in selected provinces  across the 
country and supported by the local pharmacy organisations. In addition to their collaboration, 
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incorporate CPS provision in the long term.  
Together  with  the  Consejo  and  local  organisations,  the  autonomous  communities 
(provincial government) in participating provinces have been contacted to encourage their 
cooperation. Government financial and structural support is essential to the success of the 
program in the long term. Medical organisations have also been approached at national and 
provincial levels to explain SFT and the benefits of this service to the medical profession and 
patients  to  encourage  collaboration.  Additionally,  local  health  care  team  and  individual 
collaboration  with  physicians  is  occurring,  with  meetings  being  held  by  individual 
pharmacists participating in the program. A national advisory committee to guide the program 
has  been  created,  as  well  as  advisory  committees  in  each  participating  provinces,  which 
include  representatives  from  consumer  groups,  physician  associations,  political  groups, 
universities and pharmacy associations.  
The program consists of training for participating pharmacists that cover the six levels and 
critically on-site support throughout the program. The training program has been designed in 
four parts and is provided to pharmacists over a series of days by a group of experts (Figure 
2).  
Figure 2: conSIGUE – Holistic training program 
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as  a  service  to  be  provided  through  community  pharmacy  and  the  support  from  various 
professional organizations and political bodies. The purpose of this part is to contextualize the 
need for change as well as acknowledge the support for SFT provision. In this way, it outlines 
the place of SFT within the national health policy and the support of physician representative 
organisations.  
Part 2 guides pharmacists through the strategic options available and highlights how SFT 
integrates  into  pharmacy  business  models.  The  facilitators  and  organisational  needs  of 
pharmacies  when  implementing  services  found  in  previous  research  are  discussed. 
Pharmacists are provided with practical action plans to address each issue applicable to their 
pharmacy. The return on investment of SFT provision is also outlined and pharmacists are 
provided with a guide for its calculation.  
Part 3 addresses the process of SFT provision based on the Dader method
85 and the clinical 
knowledge  required  by  pharmacists  to  evaluate  the  health  problems  of  poly  pharmacy  in 
elderly patients. The emphasis is placed on teaching the pharmacist the essential elements of 
the process and giving them an overview of the relevant clinical issues they require so they 
can apply it to their patients.  The emphasis is not placed solely on theoretical aspects of the 
process and clinical pharmacy. It includes its practical application using case example that 
pharmacists work through. The SFT service is described in detail. 
Part  4  focuses  improving  the  communication  and  collaboration  between  community 
pharmacists,  patients  and  physicians  during  the  process  of  SFT.  Firstly,  this  looks  at  the 
pharmacist-patient interaction and the behaviour change required by both to improve SFT 
outcomes. The acceptance of pharmacist-led interventions by physicians has proven difficult 
in  the  past  because  of  the  overlap  in  professional  roles.  It  is  widely  acknowledged  that 
collaboration between physicians and community pharmacists can be improved to facilitate 
the  provision  of  SFT.  Therefore,  conSIGUE  includes  a  pharmacist-physician  intervention 
aimed at improving their collaboration.  
Research has suggested that pharmacist training needs to be supported by individualised 
assistance over time to encourage CPS implementation and sustainability.
27,86 The role of a 
“formador colegial” was developed as part of the program to provide ongoing support to 
participating  pharmacists.  The  “formador  colegial”  carries  out  a  number  of  visits  to  the 
pharmacies to assess their progress with SFT and aid them with any problems they may be 
facing. This addresses the needs of pharmacists related to a number of levels in the holistic 
approach such as collaboration with physicians, patient related issues and clinical knowledge. 
The “formador colegial” performs the role of change agent to support the platform presented 
in Figure 1 and the overall holistic approach.  
CONCLUSION  
A concentric model was developed to illustrate the evolution and implementation of CPS 
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and  pharmacists  cannot  change  without  support  from  the  professional,  government  and 
stakeholder  levels.  Pharmacy  decision  makers  need  to  align  policy  changes  and  strategic 
thinking  with  practical  applications.  There  is  a  need  for  professional  organisation  to 
restructure  their  own  internal  management  systems  and  support  to  provide  sophisticated 
programs enabling community pharmacists to provide CPS. The lack of support in this area 
may result in the prevalence of product orientated model, which is more retail focused and 
currently more developed than the patient orientated model.  
The  foundation  for  change  begins  by  having  a  workforce  that  has  the  theoretical 
understanding, competency and the skills to practically apply their comprehensive knowledge. 
At the same time, pharmacists need to build their business and management skills to ensure 
that they can operate financial viable businesses. This will enhance CPS sustainability and 
will benefit the patients and society. The responsibility for initiating this change lies in the 
leadership  and  intellectual  role  of  the  universities.  The  universities  have  to  accept  their 
responsibility of being change agents for the profession through a greater relevance of the 
degrees for the profession. University research leadership will ensure that the profession take 
evidence based decisions and that they can be active partners in determining the future of 
pharmacy. The establishments of departments of pharmacy practice, with research capability, 
are necessary. If universities fail to act then the profession will be required to look outside 
faculties of pharmacy for this research.  
Once  the  foundations  are  set  the  responsibility  then  predominantly  transfers  to  the 
profession where it needs to create a practice and business environment where the patient 
orientated  model  can  prosper.  This  change  can  commence  through  the  reorganising  and 
restructuring  of  professional  organisations  to  promote  CPS  and  reduce  the  dependent  of 
product based structures. The organisational change should include a review of its internal 
political processes staffing competencies and structures. Without a change in the professional 
organisations there is a high probability that the product based community pharmacy model 
will increase its influence. Retailing and dispensing of products will be the major activity and 
business of community pharmacy leading to a possible further exclusion of pharmacist from 
the primary health care teams and an inability to serve the primary health care needs of the 
population.  
External  stakeholders  such  as  governments,  health  care  providers  and  patients  have 
recognised  that  medications  and  CPS  are  an  essential  element  of  the  health  system.    If 
pharmacists  are  medication  experts  and  community pharmacy  is  the  model  for  delivering 
medications and services to optimise their use, a change in the way the current model operates 
is required. The rate and depth of change for the profession is primarily an internal decision 
and  challenge.  It  is  through  programs  such  as  conSIGUE  that  the  holistic  and  integrated 
approach can be tested and refined. 
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